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Background: The use of Nasal Continuous Positive Airway Pressure Ventilation (NCPAP) has begun to increase and is
progressively replacing conventional mechanical ventilation (MV), becoming the cornerstone treatment for newborn
respiratory distress syndrome (RDS). Howerver, NCPAP use in Lower-Middle Income Countries (LMICs) is poor. Moreover,
bubble NCPAP (bNCPAP), for efficacy, cost effectiveness, and ease of use, should be the primary assistance technique
employed in newborns with RDS.
Objective: To measure the impact on in-hospital newborn mortality of using a bNCPAP device as the first intervention
on newborns requiring ventilatory assistance.
Methods: Design: Prospective pre-intervention and post-intervention study.
Setting: The largest Neonatal Intensive Care Unit (NICU) in Nicaragua.
Participants: In all, 230 (2006) and 383 (2008) patients were included.
Intervention: In May 2006, a strategy was introduced to promote the systematic use of bNCPAP to avoid intubation and
MV in newborns requiring ventilatory assistance. Data regarding gestation, delivery, postnatal course, mortality, length
of hospitalisation, and duration of ventilatory assistance were collected for infants assisted between May and December
2006, before the project began, and between May and December 2008, two years afterwards.
Outcome measures: The pre- vs post-intervention proportion of newborns who died in-hospital was the primary end
point. Secondary endpoints included rate of intubation and duration of NICU stay.
Results: Significant differences were found in the rate of intubation (72 vs 39%; p < 0.0001) and the proportion of
patients treated exclusively with bNCPAP (27% vs 61%; p <0.0001). Mortality rate was significantly reduced (40 vs 23%;
p < 0.0001); however, an increase in the mean duration of NICU stay was observed (14.6 days in 2006 and 17.5 days in
2008, p = 0.0481).
The findings contribute to the evidence that NCPAP, particularly bNCPAP, is the first-line standard of care for efficacy,
cost effectiveness, and ease of use in newborns with respiratory distress in LMICs.
Conclusions: This is the first extensive survey performed in a large NICU from a LMICs, proving the efficacy of the
systematic use of a bNCPAP device in reducing newborn mortality. These findings are an incentive for considering
bNCPAP as an elective strategy to treat newborns with respiratory insufficiency in LMICs.* Correspondence: maurizio.bonati@marionegri.it
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Article focus
In Lower-Middle Income Countries (LMICs), a majority
of the under-5 mortality rate is due to neonatal deaths.
Evidence presents the Nasal Continuous Positive Airway
Pressure ventilation (NCPAP) as an effective, low-cost,
and easy-to-use intervention for enhancing newborn
survival.
The objective of this study was to evaluate the effects of
using a bubble NCPAP (bNCPAP) device as the first
intervention on mortality of newborns in the largest
Neonatal Intensive Care Unit (NICU) in Nicaragua.
Key messages
 The early use of bNCPAP as the primary respiratory
assistance strategy was associated with a halved
mortality rate in newborns in NICUs, and positive
changes in medical and nursing assistance were
notable.
Strengths and limitations of this study
 This is the first wide-scale study demonstrating the ef-
ficacy of the systematic use of a low-cost bNCPAP de-
vice in a large NICU from one of the less developed
countries. The study was conducted in a natural set-
ting where clinical research and audit studies are not
common, and was therefore also a practical, educa-
tional initiative.
 The main limitations were that no risk index to state
the level of clinical severity of newborns could be
applied and that there was a lack of both data
regarding maternal socio-economic characteristics
and of a thorough analysis of the medical costs.
Background
A worldwide decrease in child mortality has been achieved
in the last few years, following the global attempt to pur-
sue Millennium Development Goal 4 (MDG4) adopted at
the UN Millennium Summit in 2000, targeting a 2/3 re-
duction in under-5 mortality by 2015. In the last decade,
however, the neonatal death rate seems to have increased
from the 37% observed in 2000 to the 42% of the overall
estimated child mortality recorded in 2010 [1]. Preterm
birth and related complications are important leading
causes of neonatal mortality.
In Lower-Middle Income Countries (LMICs), newborn
deaths are dramatically prevalent, and lack of human and
economical resources makes accomplishing the MDG4
challenging [2]. Among the interventions for reducing the
newborn mortality rate, Nasal Continuous Positive Airway
Pressure Ventilation (NCPAP) is of proven efficacy [3].The bubble NCPAP (bNCPAP), is the simplest, low-cost
respiratory support system, showing theoretical and ex-
perimental advantages, as well as similar, or greater, clin-
ical efficacy compared to other, more sophisticated
methods to deliver NCPAP (variable flow and ventilator
NCPAP) [4-9].
In addition to positive experiences from Scandinavian
countries [10], data published by the Neonatology Com-
mittee for the Developmental Epidemiology Network in
2000 have shown a significant inverse relationship between
incidence of Bronchopulmonary Dysplasia (BPD) and use
of NCPAP in very low birth weight (VLBW) newborns
[11]. NCPAP therefore seems to offer an improvement
compared to mechanical ventilation (MV) in this popula-
tion. This was the starting point for various, important tri-
als: Surfactant Positive Pressure and Pulse Oximetry
Randomized Trial (SUPPORT) [12], Cpap Or Intubation
(COIN) [13], Vermont Oxford Network (VON) [14], sUR-
factant and early nasal continuous Positive Airway Pressure
(CURPAP) [15], Colombian Network [16], and Neocosur
Network on early use of NCPAP [17]. As reviewed by W.
Carlo, this “gentle ventilation”, when started soon after
birth, appears to reduce the need for MV and the risk of
BPD/death, and is an alternative to the prophylactic or
early surfactant approach in low, very low, and extremely
low birth weight infants (ELBW) [8-10,18-22].
The use of NCPAP has begun to increase and is pro-
gressively replacing conventional MV, becoming the
cornerstone treatment for newborn respiratory distress
syndrome (RDS).
The statistical power of the few very interesting studies
addressing NCPAP use in LMICs is poor due to the
small sample sizes. All studies agree that NCPAP, par-
ticularly bNCPAP, for efficacy, cost effectiveness, and
ease of use, should be the primary assistance technique
employed in newborns with RDS [3,8,9,23-27].
Nicaragua is the second poorest country in Central
America and in 2009 the under-5 child mortality was 27/
1000 newborns (8/1000 in the USA), with a maternal mor-
tality of 100/100,000 live births. Among all causes of
under-5 mortality, in 2008, 45% was due to neonatal
causes, of which 22% were related to prematurity, 13% to
congenital anomalies, 8% to asphyxia, and 2% to sepsis
[28,29].
The Bertha Calderon Hospital (BCH), in Managua, is
the biggest maternity hospital in Nicaragua, accounting
for more than 10.000 deliveries and 600 admissions in
the neonatal intensive care unit (NICU) per year.
AMCA (Aiuto Medico Centro America) is a Swiss non-
governmental organisation that has been operating since
1985 [30] in Central America, particularly in Nicaragua
and El Salvador. From 2005 to 2007 it set up, with the
local NICU staff, a programme covering newborn resusci-
tation training courses, based on international guidelines
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tion in number of newborns on MV through the use of
the bNCPAP device. A prospective study was thus per-
formed in the largest NICU in Nicaragua to determine the
impact of the early use of low cost bNCPAP to reduce in-
tubation and MV and to determine its effects on mortality
rate and duration of NICU stay.
Methods
This study included newborns with a history of ventilatory
assistance (VA) admitted to the BCH NICU during the pe-
riods 1 May 2006 to 31 December 2006 and 1 May 2008
to 31 December 2008. During 2007, AMCA experts pro-
vided BCH staff with an extensive course on bNCPAP use,
which was repeated thereafter by local, specifically trained
staff. The impact of the intervention was therefore mea-
sured comparing the period before the project began
(2006) with that two years after the project’s start (2008).
The exclusion criteria were as follows: birth malforma-
tions, transfer to another hospital, suboptimal patient as-
sistance due to lack of devices, and parental opposition
to ventilation.
Data were collected from the infants’ medical records by
a doctor not involved in the study. Data included delivery
mode (vaginal = VAG or caesarean section = CS), gender
(M/F), gestational age (GA) and birth weight (BW), main
diagnosis at recovery, mean duration of NICU stay, recov-
ery outcome, prenatal steroids, Apgar index, resuscitation
measures, surfactant use, and age at start, and duration, of
respiratory assistance (hours).
The study population was divided into groups: 1) those
receiving only intubation and MV (MV group); 2) only
bNCPAP (bNCPAP) 3) bNCPAP first, then MV
(bNCPAP-MV); and 4) MV first, than bNCPAP (MV-
bNCPAP). The groups of patients requiring MV alone or
with bNCPAP (MV, bNCPAP-MV, MV-bNCPAP) were
categorised into an additional group called endotracheal
tube (ETT) (Figure 1).
The institutional boards of both the BCH and the
IRCCS – Istituto di Ricerche Farmacologiche Mario
Negri, Milan, Italy approved the study. Informed consent
was obtained from the parents of the infants undergoing
ventilation, in accordance with established practice.
Resuscitation and ventilatory assistance
During the study, delivery room local medical staff pro-
vided resuscitation and ventilatory assistance. Newborn
resuscitation was performed according to the American
Academy of Pediatrics and American Heart Association
guidelines [31].
No protocols or severity scores (eg. CRIB II) were de-
fined during the study period due to lack of medical de-
vices such as pulse oxymeters, blood gases analysers, and
radiographic equipment in the delivery room [32]. Thedecision to start or to continue ventilatory assistance with
MV or bNCPAP was based on clinical and anamnestic cri-
teria, according to practices aimed at limiting MV, and “the
need for supplemental oxygen in newborn infants [26].
No substantial changes in delivery room assistance or
medical or nursing staff were made during the study
period.
bNCPAP is a highly sophisticated, fluid-dynamic sys-
tem in which the bubbles produced by the expiratory
water valve improve lung mechanical characteristics and
minimise the respiratory system impedance [7,12,33].
bNCPAP kits were provided to the NICU and included
a humidifier and re-sterilisable breathing circuits (Fisher &
Paykel, New Zealand) and, to minimise infection risks, dis-
posable nasal cannula (Hudson, USA). To further reduce
costs, a dual Air/Oxygen flowmeter (Harol, Italy) was
chosen as the blender, because it is much less expensive
than automatic blenders and provides results of similar
quality.
Statistical analysis
Microsoft Office Excel 2007 and SAS system software, re-
lease 8.2, were used for analysis. Values are presented as
counts and percentages, mean ± standard deviation, or
Odd’s ratios (OR) with 95%-confidence intervals (95% CI).
A bivariate analysis was performed to evaluate the dif-
ferences observed between the two groups of ventilated
patients (2006 vs 2008). For binary variables the chi-
square test was used, while for continuous variables the
t-test was used.
GA and BW variables were grouped into classes and
transformed from quantitative into qualitative variables.
For all the statistical tests a p-value <0.05 was deemed
significant.
A multivariate logistic regression model, with the step-
wise selection option, was performed including all the
following covariates assessing the death-risk determi-
nants in VA patients: period of admission (2006 or
2008), type of ventilatory assistance (bNCPAP or ETT),
sex, GA (weeks) z-score, BW (g) z-score (z-scores were
used since birth weight was highly collinear with gesta-
tional age), mode of delivery, prenatal steroid, 1-minute
Apgar score, 5-minute Apgar score, resuscitation, and
intubation.
Lastly, the mean duration of NICU stay and of hours
of MV and bNCPAP were calculated and compared with
t-tests in the two periods of interest.
Results
A total of 651 newborns made up the study population
from the periods analysed (248 in 2006 and 403 in
2008). Of these, 18 (7.3%) in 2006 and 20 (5.0%) in 2008
(p = 0.2251) did not fit inclusion criteria, leaving 613 VA
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Figure 1 Flowchart showing patient distribution.
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The characteristics of the patients from the two groups,
described in Table 1, were all comparable except for a
greater proportion of CS delivery patients during 2008
(53% in 2006 and 69% in 2008, p = 0.0001). No patients
received surfactant treatment. In 2008 a lower propor-
tion of VA patients received resuscitation (54% in 2006
vs 39% in 2008, p = 0.0006). The 1st and 5th minute
Apgar indices were comparable in newborns who re-
ceived resuscitation at birth (RES). A higher proportion
of patients required intubation at birth in 2006
(p = 0.0410). No differences were observed in rate of ster-
oid prophylaxis use.
NICU admission diagnoses, despite the aforemen-
tioned limitations, were comparable in 2006 and 2008
(Table 2).
Ventilatory assistance mode
In 2006 the MV patient prevalence was 50% and de-
creased to 10% in 2008 (p <0.0001). During the two pe-
riods, no differences were found in the proportion of
MV-bNCPAP patients (p = 0.5467), while a significant
increase from 15% to 23% (p = 0.0202) was found in the
bNCPAP-MV group. The rate of ETT patients was 72%
in 2006 and decreased to 39% in 2008 (p <0.0001).
The introduction of bNCPAP led to an increase new-
borns treated with this device, from 28% in 2006 to 61%
in 2008 (p <0.0001), consistent with the decrease in ETT
patients (Figure 2).
In 2008, 54% of the bNCPAP newborns started treat-
ment at birth, 74% within the first, and 86% within the
second hour of life.
Mortality
In 2008 the number of VA patients admitted to the NICU
increased by 67%, but mortality decreased significantly,from 40.4% (n = 93) in 2006 to 22.7% (n = 87) (p < 0.0001).
In ETT newborns, the mortality rate remained unchanged,
from 53.0% to 53.3% (p = ns) (Figure 3). If only the MV
patient group was considered, however, mortality in-
creased from 52% in 2006 to 90% in 2008 (p < 0.0001)
(Table 3).
In the bNCPAP group deaths decreased from 7.8% in
2006 to 3.0% in 2008, but the small number of cases
does not permit statistical analyses.
In VA newborns who died in 2008, however, signifi-
cantly lower mean GA (30.7 vs 32.5 weeks) and BW
(1,383 g vs 1,633 g) were observed compared to 2006
(Table 3).
Finally, during the two periods analysed, the stepwise lo-
gistical regression model applied to the mortality-related
risk factors revealed two important inverse relationships.
The first was between the probability of death and the
5-minute Apgar score (OR = 0.68, p-value <0.0001) and
the second was between the probability of death and GA
(OR = 0.34, p-value <0.0001). Furthermore, the model re-
vealed that ventilation with bNCPAP decreased the risk of
death compared to intubation and mechanical ventilation
(ETT) (OR = 0.04, p value <0.0001), as reported in Table 4.
NICU duration of stay and ventilation mode distribution
An increase in the mean duration of NICU stay was ob-
served in VA patients: 14.6 days in 2006 and 17.5 days
in 2008 (p = 0.0481) (Table 5).
In all VA groups, the mean number of hours of the
two types of assistance given (MV and bNCPAP) were
calculated separately, including those of children receiv-
ing bNCPAP-MV and MV-bNCPAP. As shown in Table 5
all values were comparable during the two periods.
The overall number of MV and bNCPAP hours was
calculated in the two study periods, showing a 209.6%
increase in the overall bNCPAP hours in 2008 compared
Table 1 Characteristics of the newborns with ventilatory assistance (VA)
2006 2008 p
VA patients N (%) 230 (74.7) 383 (81.3) 0.0269
Sex M/F ratio 142/88 1.61 238/145 1.64 ns
CS/VAG ratio 121/109 1.11 261/119 2.19 <0.0001
Prenatal steroids N (%) 73 (33.6) 119 (31.6) ns
GA weeks, N mean ± [SD] 216 34.3 ± [3.9] 379 34.4 ± [3.8] ns
<27 N (%) 8 (3.7) 18 (4.7) ns
28-33 N (%) 73 (33.8) 112 (29.6) ns
34-36 N (%) 70 (32.4) 135 (35.6) ns
37-42 N (%) 63 (29.2) 114 (30.1) ns
>42 N (%) 2 (0.9) - - ns
BW g, N mean ± [SD] 217 1975 ± [792] 377 2001 ± [766] ns
ELBW N (%) 14 (6.5) 38 (10.1) ns
VLBW N (%) 58 (26.7) 73 (19.4) 0.0371
LBW N (%) 87 (40.1) 161 (42.7) ns
NBW N (%) 58 (26.7) 105 (27.9) ns
RES /VA 116/216 (53.7) 147/376 (39.1) 0.0006
1-minute Apgar RES N, mean + [SD] 116 5.1 ± [2.4] 144 5.5 ± [2.2] ns
5-minute Apgar RES N, mean + [SD] 116 6.9 ± [2.5] 144 7.2 ± [2.1] ns
Intubated at birth / RES (%) 29/116 (25.0) 22/147 (15.0) 0.0410
Death N (%) 93 (40.4) 87 (22.7) <0.0001
CS Caesarean section delivery.
VAG Vaginal delivery.
RES Newborns resuscitated at birth.
Rezzonico et al. BMC Pediatrics  (2015) 15:26 Page 5 of 9to 2006, due to the increase in bNCPAP newborns
(Table 5).
Discussion
In this study the interventions proposed resulted in de-
creased rates of intubation and mechanically ventilated
newborns (72 vs 39%; p = 0.0001) and in a proportionally
larger number of patients treated exclusively with
bNCPAP (27% vs 61%; p = <0.0001). Mortality rate was
significantly reduced (40.4 vs 22.7%; p = 0.0001). The aver-
age length of NICU stay in VA patients increased in 2008Table 2 Comparison of recovery diagnoses
Diagnoses 2006 (N) 2008(N) 2006 (%) 2008 (%)
Unknown 6 10 2.6 2.6
Apnoea 8 14 3.5 3.7
Asphyxia 13 19 5.7 5.0
Seizure 2 3 0.9 0.8
RDS 185 311 80.4 81.2
Sepsis and shock 15 26 6.5 6.8
Polycythaemia 1 0 0.4 0
Total 230 383 100 100
RDS includes: pulmonary bleeding, congenital pneumonia, prematurity RDS,
MAS, transient neonatal tachypnoea, pulmonary emphysema.to 2.9 days. There was a large increase in overall number
of hours of bNCPAP (209%) in 2008 compared to 2006.
Characteristics of the VA newborns
The BCH is the national referral centre for pathologic
pregnancies. During the two periods, the characteristics of
all VA patients were similar. The higher 2008 CS rate may
be explained by a generally more prudent attitude towards
term and preterm delivery during recent years [34,35] ra-
ther than by greater severity of cases in 2008. The relative
increase in CS percentage is also likely due to hospital
characteristics. Conversely, the decreased rate of newborns
requiring resuscitation (54% in 2006 and 39% in 2008) and
intubation at birth (25% in 2006 and 15% in 2008) may be
related to the greater number of CS in 2008. It was not
possible to apply a risk index [32], but no differences
emerged between 2006 and 2008 in Apgar indeces in re-
suscitated newborns, supporting comparable clinical con-
ditions in the two groups. Consistent with this hypothesis,
the multivariate analysis showed no influence of delivery
mode and newborn resuscitation on mortality. The associ-
ation between death risk and Apgar score at 5 minutes,
however, is well documented in the literature [36].
Steroid prophylaxis against RDS was the only available
prenatal care index and was comparable in the two
Figure 2 Ventilatory assistance newborns and ventilation type.
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ternal socio-economic characteristics (instruction, wealth,
parity, age, income, etc.) may be a limitation of this study.
A change in prenatal care and maternal socio-economic
conditions, however, is unlikely given the short study
period. No differences were found between 2006 and 2008
in terms of mean GA and BW, GA, MV, and 5-minute
Apgar score emerged as the most relevant factors in deter-
mining the outcome of all VA newborns.
Ventilation mode and mortality
In this study it was not possible to evaluate MV-related
lung damage, such as BPD [12,18,19], but only intub-
ation and MV impact on mortality rate.
Multivariate analysis for the most influential death-
related risk factors shows MV as one of the only three
relevant variables.Figure 3 Distribution by ventilation type and related deaths (striped)In the ETT group of patients, mortality rate remained
unchanged (53%), but the percentage of ETT patients de-
creased from 72% in 2006 to 39% during 2008, leading to
a consistent reduction in the overall mortality (Figure 3).
In the MV patient group, the death rate increased from
59% to 90%, with no impact on the overall mortality, due
to the concurrent decrease in number of newborns in this
group (from 50% to 10%).
Such high mortality rates in ventilated newborns can
be explained both by the fact that the more compro-
mised newborns received MV more frequently and by
the lack of surfactant therapy.
In the groups of MV-bNCPAP patients, bNCPAP was
applied after MV to stabilise patients and to avoid re-
intubation [4], and the rate remained very small (6% of all
VA newborns) during the periods examined, with no influ-
ence on mortality..
Table 3 Mortality rate distribution
2006 2008 p
Deaths VA 93/230 (40.4) 87/383 (22.7) <0.0001
Deaths ETT 88/166 (53.0) 80/150 (53.3) ns
Deaths MV 60/115 (52.2) 36/40 (90.0) <0.0001
Deaths MV-NCPAP 7/16 (43.7) 1/22 (4.5) 0.0054
Deaths NCPAP-MV 21/35 (60.0) 43/88 (43.9) ns
Deaths NCPAP 5/64 (7.8) 7/233 (3.0) ns
GA in VA deaths, N, mean ± [SD] 91 32.5 ± [4.2] 87 30.7 ± [4.1] 0.0043
BW in VA deaths, N, mean ± [SD] 92 1633 ± [774.7] 87 1383 ± [656.6] 0.0213
Table 5 Distribution of NICU stay and duration of
ventilation
2006 2008 p
N Mean ± [SD] N Mean ± [SD]
Days in NICU
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period were switched to MV (bNCPAP-MV group). Since
the use of bNCPAP was systematically encouraged during
2008, a consistent increase in failure incidence (15% vs
23% p = 0.02) in this group was conceivable. However, the
bNCPAP failure rate in the bNCPAP-MV group was lim-
ited and comparable with literature data [37,38]. As shown
in Table 4 the mortality rate in this group didn’t change in
the two periods. This is a clinically relevant point, since an
inappropriate delay in MV is known to compromise its ef-
ficacy and the patient’s clinical outcome.
All these considerations seem to support an appropriate
application of both ventilation methodologies during
2008.
The high success of the non-invasive respiratory support
was also associated with its early application [12,19], as
54% of the patients started at birth and 86% within the
first two hours of life. Moreover, the mean GA of new-
borns who died during 2008 was two weeks less than that
observed in 2006, further supporting the improvement in
assistance quality level.
Duration of NICU admission and distribution of
ventilation type
Mean duration of NICU stay increased by 2.9 days dur-
ing 2008 in newborns from the VA group (Table 3).
Non-respiratory impairment, infection complications,
nutritional factors, and preterm birth-related complica-
tions generate complexity in assistance and can increase
duration of NICU stay. Despite the increase in number of
VA newborns in 2008, the ETT group decreased from 72%
to 39% in 2008, representing nearly an equivalent numberTable 4 Logistic regression model for death risk and
variables considered
OR 95% CI p
bNCPAP vs ETT 0.04 (0.02 – 0.08) <0.0001
GA z-score 0.34 (0.26 – 0.44) <0.0001
Apgar score at 5 minutes 0.68 (0.59 – 0.79) <0.0001
GA z-score z score of gestational age.of newborns. For this reason, the total hours of MV for
the ETT group increased by only 7.6% (Table 3). Recent
data have shown that the rate of serious adverse events re-
lated to MV (e.g. accidental disconnection from the
respiratory circuit or unintentional removal or obstruction
of the tracheal tube) is proportional to the nursing work-
load [39]. Assistance shifted to the bNCPAP patients, ac-
counting for a 209% increase in the overall amount of
bNCPAP hours of assistance compared to 2006. The im-
proved survival that was observed was significant, but also
let to an increase in the workload in caring for patients
with bNCPAP, given the greater need for nursing staff
time and expertise. A change in clinical practices therefore
occurred, with an improvement in quality of care. The
reduced need for MV leads to a reduction in use of re-
sources, and this is especially important in settings with
resource limitations.
NCPAP in LMICs
Few studies evaluating NCPAP use in LMICs exist. Urs
and colleagues, in a prospective observational study, ob-
tained an 80% success rate using bNCPAP in 50 Indian
preterms (28–37 weeks GA), supporting the primary use
of the bNCPAP in poorer countries [40]. In a retrospective
descriptive analysis from Zimbabwe, data from 234 new-
borns (1,730 g mean BW) with a death rate incidence ofVA patients 218 14.6 ± [16.2] 376 17.5 ± [19.9] 0.0481
EET group 159 14.4 ± [16.9] 148 18.9 ± [22.3] ns
bNCPAP group 59 15.1 ± [14.6] 228 16.9 ± [18.2] ns
Hours of MV
EET group 158 101.6 ± [113.6] 149 115.9 ± [113.9] ns
Hours of bNCPAP
All bNCPAP groups 110 49.8 ± [46.7] 336 50.5 ± [69.5] ns
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spiratory support. MV resulted as the only variable associ-
ated with a significant increase in death risk when
compared to NCPAP [24].
In extreme conditions, the lack of resources leads to
restrictive criteria for access to NICUs. In South Africa,
Piepier and colleagues found that, in 21 VLBW new-
borns who were not admitted to the NICU, the intro-
duction of NCPAP support led to a significant reduction
in mortality rate, without severe complications. The au-
thors also found that, given the simplicity of the method,
it could be provided by trained nurses even in VLBW in-
fants [23]. The safety and efficacy of bNCPAP, applied
by trained nurses for reducing MV, was confirmed by
Koyamaibole [27]. A recent Indian RCT comparing
bNCPAP with ventilator NCPAP found greater success,
and comparable safety, in managing preterm neonates
with early onset respiratory distress with the first
method [8]. Despite the fact that surfactant was listed as
an essential drug by the World Health Organisation, its
use in resource limited settings is a matter of debate
[41]. Its cost is unaffordable for the health economy of
most developing countries, including Nicaragua, and
bNCPAP is an affordable and determining strategy for
reducing MV and the need for surfactant therapy. The
extremely low availability of surfactant is unacceptable
and makes the present study somewhat comparable to
the first CPAP studies, in which surfactant was not
available.
Despite the fact that the published studies had limited
statistical power due to their small population sizes, the
accumulated evidence [3,8,9,23-27,40-42] is enough to
consider NCPAP, particularly bNCPAP, as the first-line
standard of care for efficacy, cost effectiveness, and ease of
use in newborns with respiratory distress in LMICs [43].
Conclusions
This is the first study to be performed in a large NICU
from a developing country. It demonstrates an associ-
ation between the systematic use of a low-cost bNCPAP
device and a reduction in mortality and strongly sup-
ports the early use of bNCPAP as the primary respira-
tory assistance strategy when mechanical ventilation is
needed.
The proportion of bNCPAP newborns reached 61%
and mortality decreased to 22% in 2008, with no signifi-
cant differences in the populations from the two time
periods. Economic data were missing, but, as in other
LMICs with restricted health resources and high neo-
natal mortality rates, Nicaragua has limited NICU facil-
ities. The implementation of a low-cost bNCPAP
strategy represents an adequate system for avoiding in-
vasive procedures, containing the need for sophisticated
technologies, and reducing economic pressure.Ethics approval
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